AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 JUL 2 - (NewsRx.com & NewsRx.net) -- Adjuvantix Limited, a Sheffield, U.K., based vaccine adjuvant company, announced the completion of a further investment from the White Rose Technology Seedcorn Fund (WRTSF), bringing its total funding to UKP400,000.
This funding will allow Adjuvantix to extend its work on the development of its proprietary adjuvant systems to influenza vaccines.
The influenza vaccination market is currently estimated to be worth in excess of $500 million and to be growing rapidly. Because of the mode of action of the Adjuvantix vaccines, which induce immunity independent of 'toll-like' receptors, Adjuvantix expects that they will improve the efficacy of influenza vaccination ...